Incannex Healthcare Stock Price, News & Analysis
Company Description
Incannex Healthcare Inc. develops clinical-stage biopharmaceutical programs based on combination therapies and regulated botanical wellness medicine. The company’s common stock trades on Nasdaq under the symbol IXHL. Its business is centered on research and development programs for high-impact medical conditions, with company disclosures emphasizing investigational therapies for obstructive sleep apnea and generalized anxiety disorder.
The company’s lead disclosed program is IHL-42X, an investigational oral fixed-dose combination of dronabinol and acetazolamide designed for the treatment of obstructive sleep apnea. Incannex has described IHL-42X as a therapy intended to target underlying mechanisms of obstructive sleep apnea through the combined activity of its two active pharmaceutical ingredients. The program has been reported with Phase 2 clinical results, and the U.S. Food and Drug Administration has granted Fast Track Designation for IHL-42X.
Incannex also develops PSX-001, an oral fixed-dose synthetic botanical research compound formulation in development for generalized anxiety disorder. The company has reported completed Phase 2 clinical work for PSX-001 and positions the program within its broader development focus on novel therapies for serious mental-health conditions.
Incannex manages its business as one reportable and operating segment focused on research and development involving regulated botanical wellness medicine and therapies. Earlier company materials also describe an Australian license to import, export and distribute medicinal cannabis products, as well as a launched line of cannabinoid products. The company’s current public communications emphasize clinical development, regulatory interaction, capital structure, Nasdaq listing status and financing activities related to its investigational pipeline.
Corporate filings identify Incannex Healthcare Inc. as an emerging growth company and list its common stock as registered on The Nasdaq Stock Market LLC. The company has also disclosed capital-structure actions, including a completed 1-for-30 reverse stock split of its common stock and Nasdaq minimum bid price compliance matters. Its principal office is listed in Melbourne, Australia.
Stock Performance
Incannex Healthcare (IXHL) stock last traded at $3.20, down 1.85% from the previous close. Over the past 12 months, the stock has lost 49.8%. At a market capitalization of $38.9M, IXHL is classified as a micro-cap stock with approximately 12.0M shares outstanding.
IXHL Rankings
Latest News
Incannex Healthcare has 10 recent news articles, with the latest published yesterday. Of the recent coverage, 4 articles coincided with positive price movement and 5 with negative movement. Key topics include clinical trial, buybacks, partnership. View all IXHL news →
SEC Filings
Incannex Healthcare has filed 5 recent SEC filings, including 4 Form 8-K, 1 Form 10-Q. The most recent filing was submitted on June 25, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all IXHL SEC filings →
Financial Highlights
Incannex Healthcare generated $86K in revenue over the trailing twelve months, operating income reached -$23.8M (-27661.6% operating margin), and net income was -$46.9M, reflecting a -54517.4% net profit margin. Diluted earnings per share stood at $-1.35. The company generated -$12.5M in operating cash flow. With a current ratio of 2.86, the balance sheet reflects a strong liquidity position.
Upcoming Events
IHL-42X patent expiry
Incannex Healthcare has 1 upcoming scheduled event. The next event, "IHL-42X patent expiry", is scheduled for July 9, 2040 (in 5126 days). Investors can track these dates to stay informed about potential catalysts that may affect the IXHL stock price.
Short Interest History
Short interest in Incannex Healthcare (IXHL) currently stands at 834.5 thousand shares, up 4.1% from the previous reporting period, representing 8.0% of the float. Over the past 12 months, short interest has decreased by 79.7%.
Days to Cover History
Days to cover for Incannex Healthcare (IXHL) currently stands at 4.3 days, up 63.3% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 331% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 4.3 days.
IXHL Company Profile & Sector Positioning
Incannex Healthcare (IXHL) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.
Investors comparing IXHL often look at related companies in the same sector, including Scynexis (SCYX), Aytu Biopharma Inc (AYTU), Cumberland Pharmaceuticals Inc (CPIX), Talphera Inc (TLPH), and Rockwell Med Inc (RMTI). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate IXHL's relative position within its industry.